SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Madrigal Pharmaceuticals
An SI Board Since April 2018
Posts SubjectMarks Bans Symbol
138 9 0 MDGL
Emcee:  Lynn Type:  Moderated
Introduction Market Data Compact
"Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The company’s lead candidate, MGL-3196, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist in clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and familial dyslipidemias/hypercholesterolemias, among other related indications. [source: madrigalpharma.com]"

MDGL has been up well over 600% the past year!

Besides discussion and new on MDGL, discussion of other pharmaceudicals working on NASH is welcome. Some of these are VKTX, GLMD, ICPT , GNFTF , GILD, and PFE (for which there is a thread here at SI).
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
138Secondary offer by Bay City Capital, 1.38M shares (25% of their holding); finanMiljenko Zuanic-12/10/2019
137OT: GLMD I will not complain about recent stock move, but..... SCD1 and THR-betaMiljenko Zuanic-12/4/2019
136OT: GLMD All my attempt to gain info on Aramchol failed. So, this is next move..Miljenko Zuanic-11/26/2019
135OT: GLMD Disclosure In last few weeks I almost double (from 6K shares to 11K shaMiljenko Zuanic-11/22/2019
134RE: VKTX It is not that they did not disclosed, they did not run-it, so max humaMiljenko Zuanic-11/19/2019
133Their failure to disclose that animal tox data is why I never have owned VKTX intuck-11/19/2019
1325 & 10 mg QD. I did not expect anything. Let them disclose animal tox data, Miljenko Zuanic-11/19/2019
131What dosing arms were you expecting in the phase-2b?DewDiligence_on_SI-11/19/2019
130RE: VK28909, P2b <The study will target enrollment of approximately 340 patieMiljenko Zuanic-11/19/2019
129NASH blood test diagnostic from Genfit: globenewswire.com Seems that... "“Miljenko Zuanic111/10/2019
128A competitor stumbles: NGM's 24 week data show beneficial effect on LFC weaktuck-10/7/2019
127OT: GLMD Aramchol p3/4 trial design similar to MGL-3196, but with FREEDOM to havMiljenko Zuanic-9/26/2019
126Has MDGL said anything about their or others' progress in developing non-invkeokalani'nui-9/22/2019
125Oral GLP-1 agonist approval significantly alter landscape for any future NASH drMiljenko Zuanic29/20/2019
124I think that Pinnacle is main (master) CRO, and sites that are controlled by theMiljenko Zuanic-8/7/2019
123We got the regular BS this morning. NCT03900429 still showing only Pinnacle as tuck-8/7/2019
122Today it was @83...suckers....Miljenko Zuanic-7/26/2019
121Friedman want to sell company and he screwed up, so Investors are thirsty for sMiljenko Zuanic-7/22/2019
120I'd prefer your scenario, but I'm not really expecting anything other thtuck-7/22/2019
119I do not like that $70! :-( I hope it may recover after 2Q report, to 120-30 levMiljenko Zuanic-7/22/2019
118Good color regarding exposure, thanks. Technically, breaking down and may see mtuck-7/22/2019
117<about my very poor judgement > on company and managements....and first orMiljenko Zuanic-7/22/2019
116I am concerned about many thinks,.... but most of all about my very poor judgemetuck-7/22/2019
115I am concerned about many thinks,.... but most of all about my very poor judgemeMiljenko Zuanic-7/22/2019
114<5.Biopsy-proven NASH (Baseline liver biopsy) based on a liver biopsy obtaineMiljenko Zuanic-7/20/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News